Interaction Color Code
Clinical Bottom Line
Do not coadminister: Increased levels of rilpivirine
Drug 1
Drug 1 dose
25 mg daily
Drug 1 effect
RPV increased 155%; AUC increased 225%; Cmin increased 262%
Drug 2 dose
paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID
Drug 2 effect
Dasabuvir Cmax increased 18%; AUC increased 17%; Cmin increased 10%. Ombitasvir AUC increased 9%. Paritaprevir Cmin increased 30%, AUC increased 23%; Cmin decreased 5%.
Clinical Effects
Potential for QT interval prolongation with higher concentrations of RPV.
Management
Use alternative agents
Import ID
662
